This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Compared to Estimates, Illumina (ILMN) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Illumina (ILMN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of +16.67% and +1.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
by Ekta Bagri
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech
Gear Up for Illumina (ILMN) Q2 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Illumina (ILMN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
CorMedix (CRMD) Soars 5.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HRMY vs. ILMN: Which Stock Is the Better Value Option?
Agenus (AGEN) Surges 19.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Agenus (AGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Illumina Stock May Benefit From New Agreement to Acquire SomaLogic
by Zacks Equity Research
ILMN jumps 2.9% after striking a $350M deal to acquire SomaLogic and boost its fast-growing multiomics strategy.
ADRNY vs. CLX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADRNY vs. CLX: Which Stock Is the Better Value Option?
GOOS vs. IDEXY: Which Stock Is the Better Value Option?
by Zacks Equity Research
GOOS vs. IDEXY: Which Stock Is the Better Value Option?
HMY or FNV: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HMY vs. FNV: Which Stock Is the Better Value Option?
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SGIOY vs. ZTS: Which Stock Is the Better Value Option?
FTRE vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
FTRE vs. ILMN: Which Stock Is the Better Value Option?
Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach
by Moumi Mondal
TEM expands major partnerships with AZN, ILMN, and PSNL, fueling AI-driven R&D and widening its precision medicine reach.
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?
by Zacks Equity Research
ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?
by Zacks Equity Research
Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.
3 Top Genomics Stocks to Add to Your Portfolio in 2025
by Ekta Bagri
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
by Zacks Equity Research
ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.
Investing in Illumina (ILMN)? Don't Miss Assessing Its International Revenue Trends
by Zacks Equity Research
Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips
by Zacks Equity Research
ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.